PETZ Stock
PETZ Stock

Idera Pharmaceuticals, Inc. (IDRA) stock plunged 1.81% in the after-market trading session at the price of $0.82 despite no fundamental reason. The last published news was its financial results for the three months ended on 30th September 2021.

IDRA develops and commercializes drug candidates to treat rare disease conditions characterized by a small number of patients with severe unmet needs.

IDRA Third Quarter 2021 Earnings Report

On 8th November 2021, IDRA published its financial and operational results for the three months that ended on 30th September 2021.

As of 30th September 2021, IDRA reported cash of approximately $36.6 million. The company calculated a net loss of $6.0 million, or per basic and diluted share of $0.11, for the third quarter ended 30th September 2021. Net loss was $20.6 million, or per basic and diluted share of $0.59, for the third quarter of 2020.

For the third quarter of 2021, research and development costs were $3.5 million. Research and development expenses totaled $4.8 million for the same three months of 2020. General and administrative costs were $2.3 million for the three months ended on 30th September 2021. For the third quarter of 2020, IDRA reported general and administrative expenses of $2.7 million.

Management Comments

Chief Executive Officer of IDRA, Vincent Milano, remarked that they are focusing to identify more commercial-stage assets for the company’s portfolio. They are motivated by the opportunities proposed to them. They are optimistic about IDRA’s potential and will continue to preserve cash as these prospects advance. They will publish results from the second stage of ILLUMINATE-206 by the end of the year, Mr. Milano added.

IDRA Second Quarter 2021 Results

On 9th August 2021, IDRA published its financial and operational results for the second quarter ended 30th June 2021. 

IDRA calculated a net loss of  $7.6 million, or per basic and diluted share of $0.15, for the three months ended 30th June 2021. Net loss was $24.2 million, or per basic and diluted share of $0.72, for the second quarter of 2020. Research and development expenses were $3.9 million for the second quarter of 2021. General and administrative costs totaled $2.5 million for the three months ended on 30th June 2021.

LEAVE A REPLY

Please enter your comment!
Please enter your name here